PolyPid (PYPD) to Release Quarterly Earnings on Wednesday

Key Points

• PolyPid will report Q1 2026 results before the market opens on Wednesday, May 13, 2026 (conference call 8:30 AM ET); analysts expect EPS of ($0.47), following a ($0.41) loss last quarter that missed estimates.
• The stock carries a consensus rating of Moderate Buy (five Buys, one Sell) with a consensus target of $12.25, while analysts project about -$2 EPS for the current fiscal year and -$1 for the next.
• Shares opened at $4.50, trade in a 1‑year range of $2.44–$5.12, have a market cap of ~$85.9M and ~26.5% institutional ownership, with recent inflows from firms including XTX Topco and ADAR1.

PolyPid (NASDAQ:PYPD - Get Free Report) is expected to issue its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.47) per share for the quarter. Parties can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 8:30 AM ET.

PolyPid (NASDAQ:PYPD - Get Free Report) last announced its earnings results on Wednesday, February 11th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.07). On average, analysts expect PolyPid to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

PolyPid Price Performance

Shares of NASDAQ:PYPD opened at $4.50 on Wednesday. PolyPid has a 1 year low of $2.44 and a 1 year high of $5.12. The firm has a market capitalization of $85.86 million, a price-to-earnings ratio of -1.99 and a beta of 1.41. The business's 50 day moving average price is $4.37 and its 200-day moving average price is $4.19.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. XTX Topco Ltd raised its holdings in shares of PolyPid by 50.0% during the 4th quarter. XTX Topco Ltd now owns 32,661 shares of the company's stock worth $142,000 after acquiring an additional 10,888 shares during the period. ADAR1 Capital Management LLC purchased a new position in shares of PolyPid during the 4th quarter worth $451,000. Jane Street Group LLC purchased a new position in shares of PolyPid during the 4th quarter worth $66,000. HighTower Advisors LLC purchased a new position in shares of PolyPid during the 4th quarter worth $44,000. Finally, BNP Paribas Financial Markets raised its holdings in shares of PolyPid by 56.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company's stock worth $32,000 after acquiring an additional 3,500 shares during the period. Hedge funds and other institutional investors own 26.47% of the company's stock.

Analyst Upgrades and Downgrades

PYPD has been the topic of a number of recent analyst reports. Weiss Ratings lowered PolyPid from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Friday. Wall Street Zen upgraded PolyPid from a "sell" rating to a "hold" rating in a report on Saturday, March 14th. Finally, HC Wainwright restated a "buy" rating and issued a $13.00 price objective on shares of PolyPid in a report on Wednesday, February 11th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $12.25.

PolyPid Company Profile

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.